New Infusion-based Treatment for Parkinson’s Approved

10. 17. 2024

The U.S. Food and Drug Administration has approved Vyalev, an infusion-based medication, for Parkinson’s disease.

Vyalev is an infusion form of levodopa/carbidopa developed by AbbVie. Vyalev is administered under the skin using a wearable pump for advanced Parkinson’s disease patients. The administration can be 24 hours a day. It has demonstrated that it can increase control time on motor symptoms by 3 more hours compared to oral levodopa/carbidopa.

The side effects of Vyalev include redness and swelling of the infusion site, hallucinations and dyskinesia. Vyalev may also cause dizziness, lightheadedness, sleepiness, or blurred vision etc.

More reading about Vyalev